Deutsche Effecten- und Wechsel-Beteiligungsges. AG

EANS-News: DEWB investment holding: NOXXON´s SDF-1 inhibitor NOX-A12 completes Phase I

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
--------------------------------------------------------------------------------
Company Information

Subtitle: Preclinical data in models of hematological tumors to be presented at
ASH conference

Berlin, Germany, 12 December 2011 (euro adhoc) - NOXXON Pharma, a
biopharmaceutical company pioneering the development of a new class of
proprietary therapeutics called Spiegelmers, today announced the completion of
Phase I single and multiple dose clinical trials of its SDF-1 inhibitor NOX-A12.
In Phase I studies with healthy volunteers single doses of NOX-A12 up to 10.8
mg/kg and daily doses up to 2 mg/kg for five days were found to be safe and well
tolerated and resulted in dose-dependent mobilization of white blood cells and
CD34+ cells as predicted by preclinical studies. 

NOX-A12 pre-clinical results in hematological malignancies will be presented in
a talk at the annual meeting of the American Society of Hematology (ASH) in San
Diego, USA from 10-13 December 2011. Members of NOXXON´s drug development team
and collaboration partners will be at the ASH conference to explain the mode of
action and clinical potential of this innovative drug candidate. 

The titles and contributors to the three NOX-A12 presentations at ASH are as
follows:

• Oral presentation Monday, December 12, 7:15 PM; Session 652; Room 6A
L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (NOX-A12) Disrupts the Interaction
of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo, Leading to
Enhanced Sensitivity to Bortezomib 
A. M. Roccaro, A. Sacco, P. Qaung, A. Azab, P. Maiso, F. Azab, Y. Zhang, G. C.
Issa, Y. Liu, H. T. Ngo, A. Kruschinski, I. M. Ghobrial

• Poster presentation Sunday, December 11, 6:00 PM-8:00 PM; Session 711; Poster
II in Hall GH
Rapid and Efficient Mobilization of Murine Hematopoietic Stem and Progenitor
Cells with NOX-A12, a New Spiegelmers-Based CXCR4/SDF-1(CXCL12) Antagonist 
M. Scheller, F. Schwoebel, D. Vossmeyer, A. Leutz

• Poster presentation Monday, December 12, 6:00 PM-8:00 PM; Session 641; Poster
III in Hall GH
The Spiegelmer NOX-A12, a novel SDF-1 (CXCL12) inhibitor, and its effects on
Chronic Lymphocytic Leukemia (CLL) cell migration.
J. Hoellenriegel, D. Zboralski, Z. Estrov, W. G. Wierda, M. Keating, A.
Kruschinski, J. A. Burger

Based on compelling pre-clinical data in hematological and solid tumors, NOXXON
believes that NOX-A12 has the potential to be developed for treatment of
multiple oncology indications. Initiation of the first Phase IIa trial of
NOX-A12 in a hematological tumor indication is planned early in 2012, subject to
regulatory and ethics committee approvals.

- ends -

About NOXXON Pharma AG 
NOXXON Pharma is a biopharmaceutical company pioneering the development of a new
class of proprietary therapeutics called Spiegelmers. Spiegelmers are the
chemically synthesized, non-immunogenic alternative to antibodies. NOXXON has a
diversified portfolio of clinical stage Spiegelmer® therapeutics:

• NOX-E36 targets the pro-inflammatory chemokine MCP-1 (CCL2) and is currently
in Phase Ib for complications of type 2 diabetes including nephropathy.  A Phase
IIa study in diabetics with renal impairment is currently in preparation.
• NOX-A12 targets SDF-1 (CXCL12), a chemokine mediator of metastasis and
resistance to chemotherapy in cancer, and has completed Phase I. Clinical Trial
Applications have been submitted for Phase IIa studies in hematological oncology
indications.
• NOX-H94 targets hepcidin, the key regulator of iron metabolism and mediator of
iron restriction in anemia of chronic disease, and is currently in a
comprehensive single and multiple ascending dose Phase I study.

The Spiegelmer® platform provides the company with powerful and unique discovery
capabilities, which have generated a number of additional leads under
preclinical investigation. Located in Berlin, Germany, NOXXON is a well-financed
mature biotech company with a strong syndicate of international investors,
approx. 60 employees and a highly experienced management team.  

For more information, please visit: www.noxxon.com

Contact:


NOXXON Pharma AG          College Hill Life Sciences
Emmanuelle Delabre        Dr. Robert Mayer
T: +49-(0)30-726247-100   T: +49-(0)89-57001806
edelabre@noxxon.com robert.mayer@collegehill.com 

Notes for editors:

About NOX-A12

NOX-A12 specifically antagonizes stromal cell-derived factor-1 (SDF-1), a
chemokine which attracts and activates immune- and non-immune cells. SDF-1 binds
with high affinity to the chemokine receptors CXCR4 and CXCR7. The SDF-1 / CXCR4
/ CXCR7 axis has been shown to play a role in stem cell mobilization,
vasculogenesis, tumor growth and metastasis. Inhibition of the SDF-1 binding to
its receptors sensitizes tumor cells to chemotherapy and in some solid tumors
prevents invasion and metastasis, suggesting that NOX-A12 in combination with
chemotherapy could be beneficial in the treatment of various cancers.

NOX-A12 has shown promising activity in models of stem cell mobilization and
both hematological and solid tumors. In Phase I studies with healthy volunteers,
single doses of NOXXON´s SDF-1 inhibitor, NOX-A12, up to 10.8 mg/kg and daily
doses up to 2 mg/kg for five days were found to be safe and well tolerated and
resulted in dose-dependent mobilization of white blood cells and CD34+ cells as
predicted by preclinical studies. 

NOXXON received grant support within the program "KMU-innovativ" from the German
Federal Ministry of Education and Research (BMBF) for the preclinical program
and the Phase I clinical trials with NOX-A12.

Further information about the planned clinical trial in relapsed CLL patients is
available at ClinicalTrials.gov (ID: NCT01486797).


Further inquiry note:
Marco Scheidler
Tel.: +49 (0) 3641 573-3600
E-Mail: marco.scheidler@dewb-vc.com

end of announcement                               euro adhoc 
--------------------------------------------------------------------------------


company:     Deutsche Effecten- und Wechsel-Beteiligungsges. AG
             Leutragraben 1
             D-07743 Jena
phone:       +49 (0)3641 573 3600
FAX:         +49 (0)3641 573 3610
mail:     ir@dewb-vc.com
WWW:      http://www.dewb-vc.com
sector:      Financial & Business Services
ISIN:        DE0008041005
indexes:     
stockmarkets: free trade: Berlin, Stuttgart, München, Open Market / Entry
             Standard: Frankfurt 
language:   English
 



Weitere Meldungen: Deutsche Effecten- und Wechsel-Beteiligungsges. AG

Das könnte Sie auch interessieren: